-transparent.png){kind=logo}
In the investigation of the intracellular sites of insulin degradation, it might be important whether receptor-bound insulin could be a substrate for insulin-degrading enzyme (IDE). Insulin receptor and IDE were purified from rat liver using a wheat germ agglutinin column and monoclonal anti-IDE antibody affinity column, respectively. [125I]insulin-receptor complex was incubated with various amounts of IDE at 0 degree C in the presence of disuccinimidyl suberate and analyzed by reduced 7.5% SDS-PAGE and autoradiography. With increasing amounts of IDE, the radioactivity of 135 kd band (insulin receptor alpha-subunit) decreased, whereas that of 110 kd band (IDE) appeared then gradually increased, suggesting that IDE could bind to receptor-bound insulin. During incubation of insulin-receptor complex with IDE at 37 degrees C, about half of the [125I]insulin was dissociated from the complex. However, the time course of [125I]insulin degradation in this incubation was essentially identical to that of free [125I]insulin degradation. Cross-linked, non-dissociable receptor-bound [125I]insulin was also degraded by IDE. Rebinding studies to IM-9 cells showed that the receptor binding activity of dissociated [125I]insulin from insulin-receptor complex incubated with IDE was significantly (p less than 0.001) decreased as compared with that without the enzyme. These results, therefore, show that IDE could recognize and degrade receptor-bound insulin, and suggest that IDE may be involved in insulin metabolism during receptor-mediated endocytosis through the degradation of receptor-bound insulin in early neutral vesicles before their internal pH is acidified.
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
June 1984,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
June 1996,
Clinical and investigative medicine. Medecine clinique et experimentale,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
January 2015,
Cell cycle (Georgetown, Tex.),
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
February 2018,
Scientific reports,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
May 2022,
ACS chemical neuroscience,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
February 2007,
Experimental biology and medicine (Maywood, N.J.),
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
October 1997,
The American journal of physiology,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
February 2021,
International journal of molecular sciences,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
January 2021,
Biomedicines,
K Yonezawa, and
K Yokono, and
K Shii, and
J Hari, and
S Yaso, and
K Amano, and
T Sakamoto, and
Y Kawase, and
H Akiyama, and
M Nagata
June 2003,
The Journal of endocrinology,
